Introduction: overall survival of patients (pts) with chronic lymphocytic leukemia (CLL) depends not only on the severity of the CLL, the anticancer therapy used and the comorbidity of pts. The most important role in the management of these pts is played by the supervision of a cardiologist. Methods: we examined and observed in dynamics for 5 years 217 pts with CLL, constantly receiving ibrutinib, which induces arterial hypertension (AH) and atrial fibrillation (AF) in a part of the pts. All pts underwent echocardiography (ECHO), 24-hour Holter ECG monitoring (HM), assessment of comorbidity using the Charlson index and screening of fragility using the G8 questionnaire. Daily measurement of blood pressure, heart rate in the morning and in the evening with keeping a diary of measurements, was recommended for all pts, but only 81 pts were performed, who constantly contacted us remotely using instant messengers and made up an active cardiac monitoring group. Correction of treatment was carried out in accordance with these data. Results: a study of the overall survival of patients with CLL receiving ibrutinib, depending on cardiac monitoring, was carried out, starting from the first visit. The age of pts in the active cardiac monitoring group (n = 81) and in the rest of pts (n = 136) did not differ and amounted to 66.0 (60.0-70.0) years and 66.0 (59.0-74.0) years respectively. The number of men and women in the groups was comparable. In the active cardiac monitoring group, there were significantly more pts with AH - 86.5% and with AF - 42.7% compared to 50.4% with AH and 15.9% with AF in the remaining pts (p < 0.0001 in both cases) and a comparable number of pts with coronary artery disease. According to screening HM, there were more pts with short episodes of AF in the active cardiac monitoring group - 31.4% versus 8.0% in the rest of the pts (p < 0.0001). Accordingly, the number of pts receiving cardiac treatment in the active cardiac monitoring group was 87.6%, the rest was 53.6% (p <0.0001). ECHO parameters did not differ in the groups. Indicators that significantly affect survival in the general group (Charlson index, scores of the G8 questionnaire) did not have significant differences in the active cardiac monitoring group and in other pts with CLL. The groups also did not differ in hematological status and the number of cases of second tumors. Despite a significantly more pronounced cardiac comorbidity, CLL pts under active cardiac monitoring, including continuous remote monitoring, demonstrated better survival compared to other patients (p <0.0001). Conclusions: carrying out active cardiac monitoring, including constant remote observation, allows achieving higher overall survival rates for CLL pts, despite the more severe cardiac status compared to other patients under the periodic supervision of a cardiologist. Keywords: Cancer Health Disparities No conflicts of interests pertinent to the abstract.